SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response

Inclusion Criteria: * 1.Female patients with newly diagnosed breast cancer aged 18 to 70 years old; * 2.Early or locally advanced HER2-positive invasive breast cancer; * 3.Known hormone receptor status; * 4.ECOG score of 0-1; * 5.Patients who were determined by the researchers to have poor therapeutic effect after 4 cycles of neoadjuvant therapy; * 6.Organ function levels must meet the following requirements: * 7.Women of childbearing age must undergo a serum pregnancy test within 7 days before enrollment, with a negative result, and be willing to use a medically approved highly effective contraceptive method during the study and within 3 months after the last administration of the study drug. * 8.The subjects voluntarily participate in this study and sign the informed consent form. Exclusion Criteria: * 1\. Patients with metastatic or bilateral breast cancer, or inflammatory breast cancer * 2\. Patients with grade 3 or higher thrombocytopenia during previous treatment, or grade 3 or higher nausea and vomiting despite primary prevention * 3\. History of other malignant tumors (except cured carcinoma in situ of the cervix, basal cell carcinoma, etc.) and related treatment history * 4\. Patients who received major non-breast cancer surgery within 4 weeks before enrollment and have not recovered (except biopsy and PICC) * 5\. Autoimmune diseases (except special cases such as hypothyroidism and stable type 1 diabetes) * 6\. Interstitial lung disease, non-infectious pneumonia, …